COMMUNIQUÉS West-GlobeNewswire

Biodesix to Participate in Upcoming Investor Conferences
21/05/2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming [...]
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
21/05/2026
Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment of Philip Just [...]
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date [...]
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
21/05/2026
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4 th , 2026 AUSTIN, Texas, May 21 th , [...]
Zen Leaf Dispensaries Mark 10-Year Las Vegas Anniversary with “All-in-at-10” Community-Focused Celebrations May 21st-May 30th
21/05/2026
Zen Leaf will Honor and Thank the Las Vegas Community with 10 Days of Special Deals for Local Residents, Small Business Support and Special Charity Partnerships, Elvis Lookalike Contests, Giveaways and more From May 21 [...]
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
21/05/2026
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research [...]
Vitacore Announces World-First Custom-Fit CPAP Mask Following Health Canada MDL Approval
21/05/2026
FormFit™ is the world’s first end-to-end custom-fit medical grade silicone CPAP mask, creating a precision fit for each individual face. VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Vitacore, a deep [...]
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
21/05/2026
SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21/05/2026
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) [...]
Picard Medical / SynCardia Reports First Quarter 2026 Financial Results
21/05/2026
– Gross profit turns positive; Company executes significant debt reduction – -- Responds to NYSE American continued listing notice - TUCSON, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: [...]
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa ( Pa ) Secondary objectives met with no immunogenicity observed, [...]
Nanobiotix annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
BioPorto announces Interim Result for the First Quarter of 2026
21/05/2026
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), [...]
Concept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage Biotech
21/05/2026
CHAPEL-EN-LE-FRITH, United Kingdom and SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading global contract research organization (CRO) with expertise in integrated drug discovery and [...]
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
21/05/2026
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM - 212 at the 2026 ASCO® Annual Meeting First clinical data from [...]
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
21/05/2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
Déclaration Intermédiaire Premier Trimestre 2026: un début d’année sur la bonne voie, avec des avancées en matière d’innovation produits
21/05/2026
Louvain-la-Neuve, Belgique, le 21 mai 2026 - IBA (Ion Beam Applications SA), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le premier trimestre 2026. [...]
First quarter 2026 update: starting the year on track, with product innovation progress
21/05/2026
Louvain-la-Neuve, Belgium, 21 May 2026 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, shares its business update for the first quarter of 2026. Group Overview Solid commercial [...]
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
21/05/2026
Pluvicto ® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali ® NATALEE oral presentation to report prognostic and [...]

Pages